The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-Methyl-2-(4-(3-methyl-4-nitro-1-phenyl-1H-pyrazol-5-yloxy)phenyl)-1H-benzo[d]imidazole-5-carboxamide ID: ALA4063921
PubChem CID: 137634655
Max Phase: Preclinical
Molecular Formula: C25H20N6O4
Molecular Weight: 468.47
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CNC(=O)c1ccc2[nH]c(-c3ccc(Oc4c([N+](=O)[O-])c(C)nn4-c4ccccc4)cc3)nc2c1
Standard InChI: InChI=1S/C25H20N6O4/c1-15-22(31(33)34)25(30(29-15)18-6-4-3-5-7-18)35-19-11-8-16(9-12-19)23-27-20-13-10-17(24(32)26-2)14-21(20)28-23/h3-14H,1-2H3,(H,26,32)(H,27,28)
Standard InChI Key: HYKIPVYXJHYHMK-UHFFFAOYSA-N
Molfile:
RDKit 2D
35 39 0 0 0 0 0 0 0 0999 V2000
25.0220 -15.5142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.0208 -16.3338 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7289 -16.7427 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7271 -15.1054 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.4357 -15.5106 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.4405 -16.3292 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2205 -16.5777 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.6979 -15.9125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2128 -15.2532 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
28.5131 -15.9072 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9252 -16.6142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.7417 -16.6097 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.1469 -15.8990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.7297 -15.1914 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.9147 -15.1994 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.9641 -15.8931 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.3675 -15.1825 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.1786 -15.0885 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
32.3427 -14.2880 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.6320 -13.8845 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.0288 -14.4357 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.7308 -15.6909 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.4815 -16.4668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.0329 -17.0688 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.8317 -16.8920 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.0760 -16.1078 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.5229 -15.5091 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.2249 -14.2692 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.6824 -14.8804 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
29.9668 -13.4939 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.5407 -13.0724 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.3142 -15.1058 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.3140 -14.2886 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
23.6066 -15.5146 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.8987 -15.1061 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 2 0
9 5 1 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 10 1 0
8 10 1 0
13 16 1 0
16 17 1 0
17 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 17 2 0
18 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 26 1 0
26 27 2 0
27 22 1 0
28 29 2 0
28 30 1 0
21 28 1 0
20 31 1 0
1 32 1 0
32 33 2 0
32 34 1 0
34 35 1 0
M CHG 2 28 1 30 -1
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 468.47Molecular Weight (Monoisotopic): 468.1546AlogP: 4.78#Rotatable Bonds: 6Polar Surface Area: 127.97Molecular Species: NEUTRALHBA: 7HBD: 2#RO5 Violations: ┄HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 11.06CX Basic pKa: 4.38CX LogP: 4.11CX LogD: 4.10Aromatic Rings: 5Heavy Atoms: 35QED Weighted: 0.27Np Likeness Score: -1.59
References 1. Galal SA, Abdelsamie AS, Shouman SA, Attia YM, Ali HI, Tabll A, El-Shenawy R, El Abd YS, Ali MM, Mahmoud AE, Abdel-Halim AH, Fyiad AA, Girgis AS, El-Diwani HI.. (2017) Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs., 134 [PMID:28433679 ] [10.1016/j.ejmech.2017.03.090 ]